Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
Conditions: Adenocarcinoma of the Bladder; Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter; Recurrent Urethral Cancer; Regional Transitional Cell Cancer of the Renal Pelvis and Ureter; Squamous Cell Carcinoma of the Bladder; Stage III Bladder Cancer; Stage IV Bladder Cancer; Transitional Cell Carcinoma of the Bladder; Urethral Cancer Associated With Invasive Bladder CancerInterventions: Drug: sorafenib tosylate; Other: laboratory biomarker analysisSponsor: National Cancer Institute (NCI)Terminated - verified December 2012
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Research | Transitional Cell Carcinoma | Ureter and Renal Pelvis Cancer | Urethral Cancer